Glenheal Tablet is a combination pharmaceutical formulation containing Bromelain 90 mg, Trypsin 48 mg, and Rutoside 100 mg, designed to provide anti-inflammatory, proteolytic, and vasoprotective effects. Bromelain, a proteolytic enzyme derived from pineapple stems, facilitates the breakdown of proteins, thereby reducing inflammation and edema in various inflammatory conditions. Trypsin, another protease enzyme, complements Bromelain’s action by promoting the degradation of necrotic tissue and fibrin, enhancing tissue repair and reducing swelling. Rutoside, a bioflavonoid, exhibits antioxidant properties and strengthens capillary walls, contributing to improved microcirculation and reduction of capillary permeability. Glenheal is indicated for the management of acute and chronic inflammatory conditions such as postoperative edema, trauma, and sports injuries, as well as vascular disorders characterized by capillary fragility. The synergistic action of these components accelerates the resolution of inflammation, minimizes pain, and supports faster recovery. Glenheal Tablet should be administered under medical supervision, with dosage tailored according to the severity of the condition and patient response. Caution is advised in patients with hypersensitivity to any component, bleeding disorders, or concurrent anticoagulant therapy. Overall, Glenheal offers a targeted therapeutic approach to inflammation and vascular health, enhancing patient outcomes in relevant clinical scenarios.